28.09.2016 • News

Pfizer Officially Ditches Breakup Plans

As CEO Ian Read hinted earlier, Pfizer has officially ditched plans to break...
As CEO Ian Read hinted earlier, Pfizer has officially ditched plans to break into two separate publicly traded companies dedicated to mature or off-patent products and new, innovative drugs.

As CEO Ian Read hinted earlier, Pfizer has officially ditched plans to break into two separate publicly traded companies dedicated to mature or off-patent products and new, innovative drugs. The announcement ends months of speculation. As one of the arguments for not splitting, Read said during a half-year results conference in August that such a move might not help reduce Pfizer’s US tax bill. At the same time, he noted that recent corporate breakups in the pharmaceutical industry have seen a decline in the stock market valuations of the drugmakers involved.

Pfizer has already divided its business internally into the units Innovative Health and Essential Health. Chief Financial Officer Frank D’Amelio pointed earlier to the costs associated with a split, saying that in particular the “inability to realize any incremental tax efficiencies would likely be value destructive.” The company has already spent $600 million exploring strategies for a corporate breakup.

The largest US drugmaker first acknowledged having second thoughts about a breakup when the US government last year scuttled the company’s plans to acquire Dublin-based Allergan for $160 million and move its corporate headquarters to Ireland. Pfizer’s final decision, if it is final, has left analysts and other industry watchers wondering what concrete plans for growth may lie in its current strategy. The company last month won a race against other international drugmakers such as France’s Sanofi to acquire US biological drugs manufacturer Medivation, paying $14 billion.

Reacting to the drugmaker’s about-face, analysts differed in their outlook on what the future has in store for Pfizer. While some thought the company would continue to be on the prowl for fresh takeover candidates, others said they thought coming deals would be smaller. Some augurs also said they saw the move by UK competitor GlaxoSmithKline to elevate the head of its consumer division to chief executive as a sign that it, too, was abandoning breakup plans mulled earlier.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read